Drugs / NX-CP105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00361855 | Apr 2006 → ? | myocardial infarction | Neuronyx | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NX-CP105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00361855 ↗ |
| Known as | hABM-SC | “NX-CP105 (Human Adult Bone Marrow Derived Somatic Cells [hABM-SC] Administered by Endomyocardial Injection” NCT00361855 ↗ |
| Modality | Cell therapy | “NX-CP105 is a new investigational drug that is made up of these special types of bone marrow cells” NCT00361855 ↗ |
| Route | Other | “Administered by Endomyocardial Injection” NCT00361855 ↗ |